Status:
TERMINATED
Mental Health Consequences of COVID19 Infection in the French RMD Cohort
Lead Sponsor:
University Hospital, Lille
Collaborating Sponsors:
FAI²R (Auto-immune and auto-inflammatory rare diseases French network)
Conditions:
Covid19
Systemic Autoimmune Disease
Eligibility:
All Genders
18+ years
Brief Summary
this observational, cross-sectional, national, comparative study, including RMD patients followed in hospital centres of the FAI²R Rare Diseases Healthcare Pathway network and specialist private pract...
Eligibility Criteria
Inclusion
- Patient case:
- Patient with inflammatory rheumatism, systemic autoimmune or autoimmune disease
- With confirmed COVID-19 infection (at least one month prior to study inclusion)
- Study information given to the patient
- Patient affiliated to social security
- Patient control:
- Patient with inflammatory rheumatism, systemic autoimmune disease or autoimmune disease.
- Not having had a confirmed COVID-19 infection
- Study information given to the patient
- Patient affiliated to social security
Exclusion
- Opposition to participation in the study by the patient and/or his legal representative
- Adult patient not able to understand the implications and rules of the study
- Protected adults under guardianship or curatorship
Key Trial Info
Start Date :
January 20 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 19 2022
Estimated Enrollment :
296 Patients enrolled
Trial Details
Trial ID
NCT04510467
Start Date
January 20 2021
End Date
May 19 2022
Last Update
January 13 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hop Claude Huriez Chu Lille
Lille, France, 59037